Amgen Running to Win in Both Lanes of Biosimilar Race

Having pioneered the biologics pathway, Amgen Inc. is broadening its stride so it can sprint down both sides of the track in the biosimilars race, hoping to cash in on what it sees as a multibillion-dollar opportunity.